TCR² Therapeutics to Present at the BMO Prescriptions for Success Healthcare Conference

Rhea-AI Summary

On June 17, 2020, TCR² Therapeutics (Nasdaq: TCRR) announced that CFO Ian Somaiya will present updates on the company's progress at the BMO 2020 Prescriptions for Success Healthcare Conference on June 23, 2020, at 1:00 PM ET via a virtual platform. A live webcast will be available on the company's investor relations page, with an archived version accessible for 30 days post-event. TCR² focuses on novel T cell therapies for cancer patients, featuring TRuC^®-T cells that exhibit superior anti-tumor activity in clinical trials.

CAMBRIDGE, Mass., June 17, 2020 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer, today announced that Ian Somaiya, Chief Financial Officer of TCR² Therapeutics, will present an update on Company progress at the BMO 2020 Prescriptions for Success Healthcare Conference on June 23, 2020 at 1:00pm E.T. using a virtual platform.

A live webcast of the presentation will be available on the Investors page of the Company’s website at www.investors.tcr2.com. An archived replay will be available for at least 30 days following the presentation.

About TCR² Therapeutics

TCR² Therapeutics Inc. is a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer. TCR²’s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC^®-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while exhibiting lower levels of cytokine release. The Company’s lead TRuC-T cell product candidate targeting solid tumors, TC-210, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Company’s lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL). For more information about TCR², please visit www.tcr2.com.

Investor and Media Contact:

Carl Mauch
Director, Investor Relations and Corporate Communications
TCR² Therapeutics Inc.
(617) 949-5667
carl.mauch@tcr2.com 

 

FAQ

When will TCRR present at the BMO 2020 Healthcare Conference?

TCRR will present at the BMO 2020 Prescriptions for Success Healthcare Conference on June 23, 2020, at 1:00 PM ET.

How can I watch TCRR's presentation at the conference?

You can watch TCRR's presentation live on the Investors page of the company's website.

What is the focus of TCRR's clinical trials?

TCRR focuses on developing novel T cell therapies for cancer patients, with TRuC-T cells showing high anti-tumor activity in clinical trials.

What are the lead product candidates of TCRR?

TCRR's lead product candidates are TC-210 for solid tumors and TC-110 for hematological malignancies, both in Phase 1/2 clinical trials.

Where can I find more information about TCRR?

More information about TCRR can be found on their official website at www.tcr2.com.